LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

Home・Stock List・Biogen Inc

Biogen Inc

Closed

Sector Healthcare

189.62 0.35

Buy Sell

Overview

Share price change

24h

Current

Min

187.57

Max

190.13

Key metrics
By Trading Economics
Income	190M 584M
Sales	180M 2.5B
P/E Sector Avg	28.98 112.16
EPS	5.28
Profit margin	23.628
Employees	7,570
EBITDA	237M 919M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+40.53 upside

Dividends
By Dow Jones
Next Earnings	30 Oct 2024

Market Stats
By TradingEconomics
Market Cap	-100M 28B
Previous open	189.27
Previous close	189.62

News Sentiment

By Acuity

37%

63%

123 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

185.68 / 191.86 Support & Resistance

Biogen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Sept 2024, 11:00 UTC

Peer Comparison

Price change

Biogen Inc Forecast

Price Target

By TipRanks

40.53% upside

12 Months Forecast

Average 265.6 USD 40.53%

High 320 USD

Low 190 USD

Based on 22 Wall Street analysts offering 12 month price targets forBiogen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

22 ratings

Buy

Hold

Sell

Based on 22 analysts giving stock ratings to Biogen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

185.68 / 191.86Support & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

123 / 366 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.